HW&C
HC Wainwright & Co. Latest Price Targets & Analyst Ratings
# | Stock | Analyst | Price | Price Target |
Upside Downside | Rating | Date | |
---|---|---|---|---|---|---|---|---|
401 |
401
Fabrinet
FN
$13.2B
|
MC
Matthew Caufield
| $370.03 | $28 |
92%
downside
| Buy | 2 years ago |
|
402 |
402
POET Technologies
POET
$479M
|
KD
Kevin Dede
| $5.28 | $5 |
5%
downside
| Buy | 2 years ago |
|
403 |
403
Lineage Cell Therapeutics
LCTX
$279M
| $1.22 | $7 |
474%
upside
| Buy | 2 years ago |
|
|
404 |
HIVE
404
HIVE Digital Technologies
HIVE
$611M
|
KD
Kevin Dede
| $2.66 | $5 |
88%
upside
| Buy | 2 years ago |
|
405 |
405
Allogene Therapeutics
ALLO
$255M
|
DC
Debjit Chattopadhyay
| $1.15 | $29 |
2,422%
upside
| Buy | 2 years ago |
|
406 |
406
Benitec Biopharma
BNTC
$365M
|
PT
Patrick Trucchio
| $13.91 | $68 |
389%
upside
| Buy | 3 years ago |
|
407 |
407
AnaptysBio
ANAB
$613M
|
GS
Gobind Singh
| $21.90 | $35 |
60%
upside
| Buy | 3 years ago |
|
408 |
408
Celldex Therapeutics
CLDX
$1.52B
|
JH
Joseph Hafling
| $22.87 | $73 |
219%
upside
| Buy | 3 years ago |
|
409 |
409
Tyra Biosciences
TYRA
$674M
|
RS
Raghuram Selvaraju
| $12.65 | $12 |
5%
downside
| Buy | 3 years ago |
|
410 |
410
Frontline
FRO
$4.93B
|
MF
Magnus Fyhr
| $22.15 | $10 |
55%
downside
| Neutral | 3 years ago |
|
411 |
HUT
411
Hut 8
HUT
$2.68B
|
KD
Kevin Dede
| $25.38 | $25 |
2%
downside
| Buy | 3 years ago |
|
412 |
412
TORM
TRMD
$2.25B
|
MF
Magnus Fyhr
| $23.02 | $16 |
31%
downside
| Buy | 3 years ago |
|
413 |
AMRN
413
Amarin Corp
AMRN
$317M
|
AF
Andrew Fein
| $15.33 | $60 |
291%
upside
| Neutral | 3 years ago |
|
414 |
414
Scorpio Tankers
STNG
$2.71B
|
MF
Magnus Fyhr
| $53.05 | $38 |
28%
downside
| Buy | 3 years ago |
|
415 |
415
Aldeyra Therapeutics
ALDX
$334M
|
AF
Andrew Fein
| $5.56 | $15 |
170%
upside
| Buy | 3 years ago |
|
416 |
416
Ardmore Shipping
ASC
$490M
|
MF
Magnus Fyhr
| $12.04 | $8.50 |
29%
downside
| Buy | 3 years ago |
|
417 |
417
Dentsply Sirona
XRAY
$2.92B
|
YC
Yi Chen
| $14.62 | $48 |
228%
upside
| Neutral | 3 years ago |
|
418 |
418
Scholar Rock
SRRK
$3.02B
|
MK
Michael King
| $31.41 | $24 |
24%
downside
| Buy | 3 years ago |
|
419 |
419
AnaptysBio
ANAB
$613M
|
MK
Michael King
| $21.90 | $46 |
110%
upside
| Buy | 3 years ago |
|
420 |
420
Agios Pharmaceuticals
AGIO
$2.09B
|
MK
Michael King
| $36.01 | $96 |
167%
upside
| Buy | 3 years ago |
|
421 |
421
Xencor
XNCR
$610M
|
MK
Michael King
| $8.55 | $55 |
543%
upside
| Buy | 3 years ago |
|
422 |
422
Exelixis
EXEL
$10.2B
|
MK
Michael King
| $37.88 | $42 |
11%
upside
| Buy | 3 years ago |
|
423 |
423
CytomX Therapeutics
CTMX
$376M
|
RB
Robert Burns
| $2.28 | $11 |
382%
upside
| Buy | 3 years ago |
|
424 |
424
Cogent Biosciences
COGT
$1.82B
|
MK
Michael King
| $13.05 | $31 |
138%
upside
| Buy | 3 years ago |
|
425 |
425
Intellia Therapeutics
NTLA
$1.29B
|
MK
Michael King
| $12.06 | $182 |
1,409%
upside
| Buy | 3 years ago |
|